Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hunger

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44366   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: Hunger. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-004411-53 Sponsor Protocol Number: Erythromycin_v5 Start Date*: 2014-05-15
    Sponsor Name:University of Leuven
    Full Title: Brain mechanisms underlying the effect of the motilin receptor agonist erythromycin on hunger in normal weight subjects
    Medical condition: The effect of erythromycin administration on hunger and brain responses will be tested in healthy volunteers
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001949-13 Sponsor Protocol Number: LIRHV Start Date*: 2019-01-31
    Sponsor Name:KU Leuven
    Full Title: The effect of liraglutide on MMC activity, gastrointestinal hormones, hunger ratings and ad libitum food intake in healthy volunteers
    Medical condition: The study will focus on the underlying mechanisms of obesity. The effects will first be investigated in healthy, lean volunteers.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004082-33 Sponsor Protocol Number: erythstom2 Start Date*: 2011-10-05
    Sponsor Name:UZLeuven
    Full Title: The role of induced phase 3 contractions in the control of hunger and food intake
    Medical condition: Gastrointestinal contractility will be studied in healthy volunteers for 7 hours in a fasting condition
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004600-35 Sponsor Protocol Number: Modifast3 Start Date*: 2012-12-19
    Sponsor Name:KULeuven
    Full Title: Effect of diet-induced weight loss on motilin, ghrelin, bitter taste perception, hunger and the migrating motor complex: a prospective study
    Medical condition: Gastrointestinal contractility and hormones will be studied in obese patients before and after weight loss induced by a diet
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004946-41 Sponsor Protocol Number: s57223 Start Date*: 2014-11-19
    Sponsor Name:KULeuven
    Full Title: The influence of GLP-1 analog, liraglutide, on gastric accommodation, gastric emptying, hunger and the migrating motor complex in healthy volunteers
    Medical condition: healthy volunteers no medical condition; drug will be studied because it is known to influence gastric motility
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004978-95 Sponsor Protocol Number: VildaMMC Start Date*: 2014-03-12
    Sponsor Name:KULeuven
    Full Title: the influence of a DPP-4 inhibitor, vildaglitpin, on hunger and the migrating motor complex in healthy volunteers
    Medical condition: healthy volunteers no medical condition, drug will be studied because they are known to influence gastric motility
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007970-47 Sponsor Protocol Number: fMRI-Ex-4 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: Central nervous effects of exendin-4 on hunger and satiety in obesity and diabetes mellitus type 2: an fMRI study
    Medical condition: Obesity (N=20) vs. obesity with type 2 diabetes (N=20); Randomised + controlled + cross-over + prospective + double-blind + stratified + 2 arms: Exendin-4 vs NaCl 0.9% iv ober 100 minutes on two s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029885 Obesity, unspecified LLT
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002855-12 Sponsor Protocol Number: RM-493-034 Start Date*: 2022-04-22
    Sponsor Name:Rhythm Pharmaceuticals Inc.
    Full Title: A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Rece...
    Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-004107-32 Sponsor Protocol Number: RM-493-030 Start Date*: 2023-01-23
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects with Hypothalamic Obesity
    Medical condition: Hypothalamic Obesity
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002320-83 Sponsor Protocol Number: RM-493-012 Start Date*: 2016-09-28
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesi...
    Medical condition: Early onset pro-opiomelanocortin deficiency obesity
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-005006-35 Sponsor Protocol Number: RM-493-022 Start Date*: 2018-05-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 recepto...
    Medical condition: Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genet...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003083-30 Sponsor Protocol Number: PLAQHV Start Date*: 2019-01-31
    Sponsor Name:UZ Leuven
    Full Title: The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects
    Medical condition: The study is meant to have a better understanding in obesity and how we can prevent/cure it. Therefore, the product will first be tested in healthy, lean volunteers.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003107-65 Sponsor Protocol Number: OPNT001-BN-001 Start Date*: 2017-01-11
    Sponsor Name:Opiant Pharmaceuticals Inc
    Full Title: Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa
    Medical condition: Bulimia nervosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10006550 Bulimia nervosa PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000387-14 Sponsor Protocol Number: RM-493-014 Start Date*: 2017-05-24
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity
    Medical condition: - POMC/PCSK1/LEPR heterozygous - POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesity - POMC/PCSK1/LEPR composite heterozygous deficiency obesity - Smith-Magenis Syndrome - SH2B1...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) FR (Ongoing) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-003887-31 Sponsor Protocol Number: 2004/116 Start Date*: 2004-12-09
    Sponsor Name:Klinisk Farmakologisk Center og Med. Afd. M, Århus Sygehus, NBG
    Full Title: "Farmakodynamiske egenskaber af to langtidsvirkende insulinanaloger i sammenligning med NPH insulin"
    Medical condition: Healthy subjects.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004381-18 Sponsor Protocol Number: 2012/1226 Start Date*: 2013-06-04
    Sponsor Name:St Olavs Hospital Trondheim University Hospital
    Full Title: Treatment of morbid obesity through intra-gastric injections of Botulinum toxin A: A pilot study
    Medical condition: Morbid obesity (obesity class 3)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004058-11 Sponsor Protocol Number: RM-493-023 Start Date*: Information not available in EudraCT
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström syndrome (AS) Patients with Moderate to Severe Obesity
    Medical condition: Obesity and hyperphagia in patients with Bardet-Biedl Syndrome or Alström syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-002873-24 Sponsor Protocol Number: RM-493-035 Start Date*: 2022-05-16
    Sponsor Name:Rhythm Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melano...
    Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000753-24 Sponsor Protocol Number: DC2011LiBrain001 Start Date*: 2011-10-13
    Sponsor Name:VU University Medical Center
    Full Title: Central effects of endogenous GLP-1 and the GLP-1 analog liraglutide on brain satiety and reward circuits and feeding behavior in diabetes.
    Medical condition: diabetes mellitus obesity
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    16.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022334-92 Sponsor Protocol Number: qmul250510 Start Date*: 2011-01-07
    Sponsor Name:Barts and the London School of Medicine and Dentistry, Queen Mary University of London
    Full Title: Effects of a combination of varenicline and transdermal nicotine patch on post-quitting urges to smoke
    Medical condition: Tobacco dependence (smoking cessation)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Dec 16 13:09:05 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA